Participant flow

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody · Source last updated 2021-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Phase I: Dose Escalation 1-5 mCi in 50mg of antibody

   id

   FG000

   title

   Phase I: Dose Escalation 1-5 mCi in 50mg of Antibody

2. description

   Phase I: Dose Escalation 1-5 mCi in 20mg of antibody

   id

   FG001

   title

   Phase I: Dose Escalation 1-5 mCi in 20mg of Antibody

3. description

   Phase I: Dose Escalation 1-5 mCi in 3-50mg of antibody

   id

   FG002

   title

   Phase I: Dose Escalation 1-5 mCi in 3-50mg of Antibody

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         7

      3. group Id

         FG002

         num Subjects

         1

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         7

      3. group Id

         FG002

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The Phase I portion of the study has concluded. The Phase II portion will not open due to the study PI leaving the institution.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice